On May 21, 2025, JMP Securities analyst Silvan Tuerkcan reiterated a "Market Outperform" rating for CRISPR Therapeutics (CRSP, Financial). The analyst maintained a price target of $86.00 USD, consistent with the prior target.
The consistent rating and price target reflect the firm's sustained confidence in CRISPR Therapeutics' market performance. The stock is anticipated to outperform its peers in the market, according to JMP Securities.
CRISPR Therapeutics (CRSP, Financial) continues to attract attention from investors and analysts alike, with its ongoing developments and strategic market positioning.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 22 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.05 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 103.94% from the current price of $39.25. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.3, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $31.77, suggesting a downside of 19.06% from the current price of $39.25. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
